<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02853084</url>
  </required_header>
  <id_info>
    <org_study_id>HL_C201</org_study_id>
    <nct_id>NCT02853084</nct_id>
  </id_info>
  <brief_title>HL2351 CAPS Phase II Study</brief_title>
  <official_title>An Open Label, Single Arm Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of HL2351 in Patients With Cryopyrin Associated Periodic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Handok Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Handok Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single arm trial to evaluate the efficacy, safety, and
      pharmacokinetics of HL2351 in patients with cryopyrin associated periodic syndromes (CAPS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial enrolls patients with CAPS being on stable dose of anakinra daily and then switch
      over HL2351 given once weekly. It consists of 4 phases, 6-week screening, single dose PK,
      6-month multiple dose, and 18-month extension phase.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficult of recruiting
  </why_stopped>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Diary Symptom Sum Score (DSSS)</measure>
    <time_frame>from baseline to Month 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in SAA, CRP, ESR levels</measure>
    <time_frame>from baseline to Month 6, from baseline to each visit up to Month 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in physician's global assessment of autoinflammatory using 100mm VAS score disease</measure>
    <time_frame>from baseline to Month 6, from baseline to each visit up to Month 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in patient's(parents or legal guardians) global assessment of autoinflammatory using 100mm VAS score disease</measure>
    <time_frame>from baseline to Month 6, from baseline to each visit up to Month 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile(Cmax)</measure>
    <time_frame>0,12,24,36,48,72,96,144,168 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile(AUClast)</measure>
    <time_frame>0,12,24,36,48,72,96,144,168 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile(AUCinf)</measure>
    <time_frame>0,12,24,36,48,72,96,144,168 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile(Tmax)</measure>
    <time_frame>0,12,24,36,48,72,96,144,168 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile(t1/2)</measure>
    <time_frame>0,12,24,36,48,72,96,144,168 hr</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Cryopyrin‑Associated Periodic Syndromes (CAPS)</condition>
  <arm_group>
    <arm_group_label>HL2351</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL2351</intervention_name>
    <description>The dose will be adjusted based on disease activities</description>
    <arm_group_label>HL2351</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented molecular diagnosis of NALP3 mutation or diagnosis of CAPS based on sign
             and symptom

          -  Diagnosis of CAPS based on signs and symptoms

          -  Current stable doses of anakinra, alone or in combination with methotrexate or
             corticosteroids

        Exclusion Criteria:

          -  Patient been diagnosed with a hereditary periodic fever syndrome or autoinflammatory
             disease other than CAPS

          -  Patients whose disease is inadequately controlled on current stable doses of anakinra,
             alone or in combination with methotrexate or corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JOONG GON KIM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Handok Inc.</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Auto-inflammatory diseases</keyword>
  <keyword>IL-1 inhibitors</keyword>
  <keyword>HL2351</keyword>
  <keyword>Cryopyrin‑Associated Periodic Syndromes (CAPS)</keyword>
  <keyword>Neonatal Onset Multisystem Inflammatory Disease (NOMID)</keyword>
  <keyword>Muckle-Wells Syndrome (MWS)</keyword>
  <keyword>Familial Cold Autoinflammatory Syndrome (FCAS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

